BioMarin says FDA to delay deciding on approval of DMD drug

23 Dec 2015 | Author: | No comments yet »

Analysts Set BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) PT at $148.28.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has received a consensus recommendation of “Buy” from the twenty-three ratings firms that are currently covering the stock, MarketBeat Ratings reports. Food and Drug Administration (FDA) has notified the Company that they had not yet completed their review process and would be unable to take an action by the Prescription Drug User Fee Act (PDUFA) action date for KyndrisaTM (drisapersen) of December 27, 2015, and anticipate taking action in early January 2016.

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. Wedbush reaffirmed a “hold” rating and issued a $137.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday, October 30th. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements.

BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise. Jennison Associates now owns 150,000 shares of the company’s stock valued at $15,798,000 after buying an additional 30,000 shares in the last quarter. Vetr cut BioMarin Pharmaceutical from a “strong-buy” rating to a “buy” rating and set a $126.54 price objective for the company. in a report on Wednesday, October 28th.

Disclaimer: The views, opinions, and information expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any company stakeholders, financial professionals, or analysts.. Its approved products are Vimizim (), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://putnamstandard.com/2015/12/18/analysts-set-biomarin-pharmaceutical-inc-nasdaqbmrn-pt-at-148-28/695036/

Here you can write a commentary on the recording "BioMarin says FDA to delay deciding on approval of DMD drug".

* Required fields
Twitter-news
Our partners
Follow us
Contact us
Our contacts

About this site